Head-to-head · WeighScore
Breeze Meds vs Hims & Hers
The verdict
Hims & Hers takes it — 75.6/100 to 72.4/100.
Hims & Hers grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Mass-market app-first program with nationwide reach and consumer-grade polish.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | Breeze Meds | Hims & Hers |
|---|---|---|
| WeighScore | 72.4/100 | 75.6/100 |
| Grade | C | C |
| Site position | #90 | #56 |
| Semaglutide | From $199/mo | $199/mo |
| Tirzepatide | From $299/mo first month, $399/mo thereafter | Not disclosed |
| Coverage | All 50 states | All 50 states |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Not confirmed | Not confirmed |
Site position #90 · C
Strengths
- Nothing charged until a provider approves you, and the consult is free if you go ahead
- One inclusive price covering consult, medication, supplies, shipping and support
- LegitScript certified, all 50 states, cancel or change plan at any time
- NAD+ injections offered alongside the GLP-1 line
Where it loses points
- The public site names no molecule behind its "from $199" — tirzepatide pricing appears only inside the intake
- Every quoted figure is for the LOWEST dose; the funnel says higher doses may cost more
- An $80 consultation fee applies if you are approved and then decline
- Injection only, compounded only, with no published lab program
Site position #56 · C
FDAWarning letter issued to Hims & Hers Health, Inc. dba Hims in September 2025. See the FDA warning-letter database.
Strengths
- Nationwide
- Polished app
- Strong brand trust
Where it loses points
- Tirzepatide pricing inconsistently disclosed
- Industry-wide compounding scrutiny
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). CoreAge Rx advertises flat dose pricing for compounded injections, with no membership fee; its consultation-fee and refund deadlines deserve a close read before paying.
Commercial relationships affect this placement. The score comparison above is separate.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.